Peptide Seller Jailed for Steroid Scams

Matthew Kawa, the owner of Paradigm Peptides, was sentenced to nearly six years in federal prison on July 31, 2026, for building a massive business on deception and selling adulterated products. He pleaded guilty to selling unapproved drugs and illegally importing them, a rare criminal penalty for sellers in the largely unregulated "research use only" peptide market.

U.S. District Court Judge Cristal Brisco sentenced Kawa to 70 months, citing his focus on business over customer safety and his disregard for regulatory warnings. Paradigm Peptides, which operated until March 2024, reportedly had 54,000 customers across all 50 U.S. states and 80 countries. Kawa also agreed to forfeit $5 million.

The company imported products from China and India, forging laboratory certificates to enhance credibility. Prosecutors revealed that six testosterone-mimicking compounds tested by the government all contained actual testosterone. Kawa admitted Paradigm's products were marketed for human consumption, despite the "research use only" disclaimer.

Kawa's sister and employee, Jennifer Stechkober, received a 16-month sentence for her integral role in the business's false statements. The prosecution hopes this severe penalty will deter similar conduct in the booming peptide industry, which increasingly sees compounds migrating into mainstream use despite lacking FDA approval.

One customer, Dan Murphy, detailed his harrowing experience, suffering steroid-induced psychosis, paranoia, and suicidal thoughts after taking Paradigm's SARMs, which independent testing later confirmed contained testosterone. Murphy is now suing Paradigm Peptides and Kawa. The case underscores the significant risks associated with unregulated peptide vendors, with authorities likening prosecution efforts to a "game of whack-a-mole" due to new, similarly named websites appearing even after Paradigm's closure.